“…In the same way, a role as a hub and drug target appeared recursive for some specific genes. In addition to ACE2, Interleukin-6 (IL6) [ 79 , 90 , 96 , 97 , 99 , 100 ], vascular endothelial growth factor A (VEGFA) [ 23 , 77 , 97 , 100 , 101 ], transcription factor p65 (RELA) [ 75 , 90 , 91 , 94 , 96 , 101 ], signal transducer and activator of transcription 1-alpha/beta (STAT1) [ 26 , 75 , 83 , 93 , 100 ], mitogen-activated protein kinase 1 (MAPK1) [ 16 , 91 , 94 , 96 , 100 ], MAPK8 [ 90 , 91 , 96 , 100 ], mitogen-activated protein kinase 3 (MAPK3) [ 91 , 94 , 97 ], proto-oncogene tyrosine-protein kinase Src (SRC) [ 26 , 91 , 97 ], epidermal growth factor receptor (EGFR) [ 90 , 91 , 97 ] and RAC-alpha serine/threonine-protein kinase (AKT1) [ 78 , 91 , 94 ] were among those best ranked following network topology, molecular docking and molecular dynamic analyses—all results that highlight the enrichment and involvement of the MAPK [ 23 , 100 , 101 ], PI3K-Akt [ 24 , ...…”